Wedbush Securities Inc Editas Medicine, Inc. Transaction History

Wedbush Securities Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 13, 2022	SELL	$26.55 - $40.57 $149,078 - $227,800	-5,615 Closed	0 $0
Q3 2021 Oct 08, 2021	BUY	$39.27 - $72.94 $11,781 - $21,882	300 Added 5.64%	5,615 $230,000
Q2 2021 Jul 27, 2021	BUY	$31.29 - $56.64 $166,306 - $301,041	5,315 New	5,315 $301,000
Q1 2021 Apr 26, 2021	SELL	$39.71 - $90.58 $160,428 - $365,943	-4,040 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $109,362 - $340,774	4,040 New	4,040 $283,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.